Drug-associated dermatomyositis following ipilimumab therapy: a novel immune-mediated adverse event associated with cytotoxic T-lymphocyte antigen 4 blockade
…, DJ Todd, A Werchniak, RA Vleugels - JAMA …, 2015 - jamanetwork.com
Importance Ipilimumab, a human monoclonal antibody targeted against cytotoxic T-lymphocyte
antigen 4, has shown promise in the treatment of metastatic melanoma. However, given …
antigen 4, has shown promise in the treatment of metastatic melanoma. However, given …
Eosinophilic fasciitis: an updated review on diagnosis and treatment
DR Mazori, AN Femia, RA Vleugels - Current rheumatology reports, 2017 - Springer
Purpose of Review First recognized in 1974, eosinophilic fasciitis (EF) is a fibrosing disorder
of the fascia with characteristic cutaneous and hematologic manifestations. This review …
of the fascia with characteristic cutaneous and hematologic manifestations. This review …
Treatment options for pityriasis rubra pilaris including biologic agents: a retrospective analysis from an academic medical center
Methods| Using the university-based Partners Healthcare Research Patient Data Registry,
we identified all patients with PRP seen by a dermatologist from January 2000 through …
we identified all patients with PRP seen by a dermatologist from January 2000 through …
Evaluation of the effectiveness and tolerability of mycophenolate mofetil and mycophenolic acid for the treatment of morphea
…, A Laumann, JM Yu, J Zhao, RA Vleugels… - JAMA …, 2020 - jamanetwork.com
Importance First-line systemic therapy for morphea includes methotrexate with or without
systemic corticosteroids. When this regimen is ineffective, not tolerated, or contraindicated, a …
systemic corticosteroids. When this regimen is ineffective, not tolerated, or contraindicated, a …
Anti-melanoma differentiation–associated gene 5 (MDA5) dermatomyositis: a concise review with an emphasis on distinctive clinical features
DJB Kurtzman, RA Vleugels - Journal of the American Academy of …, 2018 - Elsevier
Melanoma differentiation–associated gene 5 (MDA5) is a recently described autoantigen
target in a subset of patients with dermatomyositis. Anti-MDA5 dermatomyositis is …
target in a subset of patients with dermatomyositis. Anti-MDA5 dermatomyositis is …
A systematic review and meta-analysis to inform cancer screening guidelines in idiopathic inflammatory myopathies
…, J Schmidt, S Tansley, RA Vleugels… - …, 2021 - academic.oup.com
Objectives To identify clinical factors associated with cancer risk in the idiopathic inflammatory
myopathies (IIMs) and to systematically review the existing evidence related to cancer …
myopathies (IIMs) and to systematically review the existing evidence related to cancer …
Calciphylaxis: a systematic review of existing and emerging therapies
C Vedvyas, LS Winterfield, RA Vleugels - Journal of the American Academy …, 2012 - Elsevier
Calciphylaxis, also known as calcific uremic arteriolopathy, is a cutaneous ischemic small
vessel vasculopathy seen in 1 to 4% of patients with chronic kidney disease on hemodialysis. …
vessel vasculopathy seen in 1 to 4% of patients with chronic kidney disease on hemodialysis. …
Tofacitinib citrate for refractory cutaneous dermatomyositis: an alternative treatment
Methods| We identified patients with multidrug-resistant cutaneous dermatomyositis and
assessed their response to treatment with twice-daily oral tofacitinib. Improvement was …
assessed their response to treatment with twice-daily oral tofacitinib. Improvement was …
Safety of systemic agents for the treatment of pediatric psoriasis
…, E Siegfried, S Philipp, Z Szalai, RA Vleugels… - JAMA …, 2017 - jamanetwork.com
Importance Use of systemic therapies for moderate to severe psoriasis in children is increasing,
but comparative data on their use and toxicities are limited. Objective To assess patterns …
but comparative data on their use and toxicities are limited. Objective To assess patterns …
Dermatomyositis: an update on diagnosis and treatment
GA Cobos, A Femia, RA Vleugels - American Journal of Clinical …, 2020 - Springer
Dermatomyositis is a rare inflammatory disease with characteristic cutaneous findings and
varying amounts of systemic involvement. Patients may present with skin disease alone, have …
varying amounts of systemic involvement. Patients may present with skin disease alone, have …